BioHarvest Sciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $34.5M+37.0% YoYTTM through 31 Dec 2025
Net Income -$11.1MTTM through 31 Dec 2025
Free Cash Flow -$9.6MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 59.3% |
| EBITDA Margin | -11.4% |
| Operating Margin | -16.2% |
| Net Margin | -32.3% |
Returns
-43.8%ROE
-23.4%ROA
Balance Sheet Health
Debt / Equity0.55x
Current Ratio3.97x
Net Debt-$15.3Mnet cash position
Cash & Equivalents$23M
Quality Metrics
Altman Z-Score-1.32
Piotroski F-Score5 / 9
FCF Margin-27.8%
Rule of 40-3.5
Earnings-Beat Rate50.0%
Dividend
No dividend
Capital Allocation
R&D Spend$5.3M
Capex Intensity6.8%
Segment Performance
Figures as of 31 Dec 2025
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| D2C Products | View detailsFocusing on optimizing performance and expanding the 'VINIA inside' product portfolio. | ||
| CDMO Services | View detailsExpected to drive a step change in revenue growth and financial performance in 2026 and beyond. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.